IDRx is a clinical-stage biopharmaceutical company dedicated to improving cancer treatment through precision therapies. Established in 2021, the company focuses on developing highly selective and potent treatments that address the shortcomings of current cancer medications, particularly by targeting mechanisms that enable tumors to evade treatment. Their lead candidate, IDRX42, targets specific genetic mutations associated with gastrointestinal stromal tumors (GISTs). IDRx's leadership team has a wealth of experience in drug discovery, development, and commercialization, contributing to over ten approved therapeutics. With a commitment to innovation in cancer care, IDRx values collaboration, integrity, and a strong dedication to patient outcomes. Their dynamic work environment supports team engagement primarily through remote collaboration, with opportunities for in-person interaction in Cambridge, MA.